Abstract

A hybrid oncocytic/chromophobic tumor or a low malignant oncocytic tumor is not officially included in the clas- sification of 2016 WHO kidney tumors, however, in the literature, some authors consider this tumor as an independent nosological unit. A number of authors describe a hybrid oncocytic / chromophobic tumor consisting exclusively of relatively small oxyphilic cells resembling both oncocytes and chromophobic renal carcinoma cells at the same time. The development of morphological and immunohistochemical criteria for a hybrid oncocytic / chromophobic tumor is an important link in the differential diagnosis of renal cell carcinomas with oncocytic morphology. The aim of the study is a comparative analysis of the morphological, histochemical, immunophenotypic parameters of oncocytoma, chromophobic renal cell carcinoma and hybrid oncocytic / chromophobic tumor. Materials and methods. The study was performed on operational material from 162 patients undergoing surgical treatment at the Urological Clinic I. M. Sechenov and the Urology Center of the Scientific Clinical Center (NCC) of Russian Railways for kidney oncocytoma and chromophobic renal cell carcinoma from 2011 to 2017. Immunohistochemical studies were performed on paraffin sections according to the standard protocol. Antibodies used: EABA, Caveolin-1, MOC31, CyclinD1, CD10, CD117, EpCAM, CK7, DOG1, CAM5.2, CK19, E-Cadherin, Parvalbumin, KSC, PAX2, PAX8, S100A1 and MUC-1. Results. Based on the performed morphological and immunohistochemical analysis of 162 tumors in 61 (38%) cases revealed oncocytoma, in 35 (22%) showed cases classical chromophobic renal cell carcinoma, in 59 (36%) samples eosinophilic chromophobic renal cell carcinoma and 7 (4%) cases had a hybrid oncocytic/ chromophobic tumor. Conclusion. In some cases, a hybrid oncocytic / chromophobic tumor can be represented exclusively from “hybrid” cells with borderline signs of oncocytoma and eosinophilic chromophobic renal cell carcinoma.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call